TABLE 2.
The Association Between β Blockers (Overall) and the Risks of Neonatal Hypoglycemia and Neonatal Bradycardia
β Blocker Exposed | β Blocker Nonexposed | OR (95% CI) | |||
---|---|---|---|---|---|
Outcomes | Total | Outcomes | Total | ||
Neonatal hypogylcemia | |||||
Unadjusted | 460 | 10 585 | 27 228 | 2 281 531 | 3.76 (3.42–4.13) |
PS-matched | 459 | 10 561 | 834 | 31 683 | 1.68 (1.50–1.89) |
Neonatal bradycardia | |||||
Unadjusted | 165 | 10 585 | 11 659 | 2 281 531 | 3.08 (2.64–3.6) |
PS-matched | 165 | 10 561 | 385 | 31 683 | 1.29 (1.07–1.55) |